Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis

The survival outcomes in HER2-low versus HER2-zero breast cancer (BC) after neoadjuvant chemotherapy (NACT) remain unclear. The meta-analysis was conducted to summarize current evidence about the survival outcomes in HER2-low versus HER2-zero BC. We conducted a systematic search in PubMed and EMBASE databases to identify relevant studies. A total of 14 studies with 53,714 patients were included. Overall, 34,037 patients (63.37